Skip To Main Content
Rimal Ilyas on Muck Rack

Rimal Ilyas

As seen in: Nature, Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Rimal Ilyas’s profile

Articles by Rimal Ilyas

CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients

|
By Saubia Fathima, Lior Rokach, Nour Ghosoun, Mahsa RezaSoltani, Rimal Ilyas, Ali Alsugair, Kristen B. McCullough, Maymona G. Abdelmagid, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Aasiya Matin, Antoine Saliba, Mehrdad Hefazi Torghabeh, Mark Litzow, William Hogan, Mithun V. Shah, Mrinal Patnaik, Animesh Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Jeanne Palmer, Nathan Punwani, Lisa Sproat, Nandita Khera, Ayalew Tefferi, Naseema Gangat Verified, Cecilia Arana Yi
| Nature Verified
Abstract The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current study, we retrospectively examined outcomes of 600 patients with newly diagnosed AML treated with CPX-351 (N = 112) or Ven-HMA (N = 488).
Open in Who Shared Issue with article?

Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies

|
By Naseema Gangat Verified, Amritpal Singh, Rimal Ilyas, Giuseppe Gaetano Loscocco
| Wiley Online Library Verified
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. Supporting Information Filename Description ajh27416-sup-0001-supinfo.docxWord 2007 document , 38.9 KB Table S1. Maternal complications in 26 of 200 pregancices in 100 women with essential thrombocythemia. Table S2. Fetal complications in 13 of 200 pregnancies in 100 women with essential thrombocythemia. Table S3.
Open in Who Shared Issue with article?
Show More